Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor

• US 7,527,962 B2
• Filed: 12/07/2005
• Issued: 05/05/2009
• Est. Priority Date: 12/19/2001
• Status: Expired due to Term

• Current Assignee: Millennium Pharmaceuticals Incorporated (Takeda Pharmaceutical Company Limited)
• Original Assignee: Millennium Pharmaceuticals Incorporated (Takeda Pharmaceutical Company Limited)
• Inventors: Gimeno, Ruth E., Kapeller-Libermann, Rosana, Hubbard, Brian K., Wu, Zhidan
• Primary Examiner(s): Nashed; Nashaat T
• Assistant Examiner(s): CHOWDHURY, IQBAL HOSSAIN
• Application Number:
  US11/296,615
• Publication Number:
  US 20060183210A1
• Time in Patent Office: 1,245 Days
• Field of Search: 435/193, 435/6, 435/15, 435/69.1, 435/134, 435/320.1, 435/252.3, 435/257.2, 536/23.2
• US Class Current: 435/252.3
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C07K 16/40 against enzymes
• CPC Class Codes: C12N 9/1029 transferring groups other than amino-acyl groups (2.3.1)
• CPC Class Codes: C12Q 1/48 involving transferase
• CPC Class Codes: C12Y 203/0102 Diacylglycerol O-acyltransferase (2.3.1.20)
• CPC Class Codes: G01N 2333/91051 Acyltransferases other than aminoacyltransferases (general) (2.3.1)
• CPC Class Codes: G01N 2800/044 Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
• CPC Class Codes: G01N 33/573 for enzymes or isoenzymes

Abstract

The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.

Claims

1. An isolated nucleic acid selected from the group consisting of:

a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO;

7; and

b) a nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO;

8.

2. The nucleic acid of claim 1, wherein the nucleic acid comprises the nucleotide sequence of SEQ ID NO:

7.

3. The nucleic acid of claim 1, wherein the nucleic acid encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:

8.

4. The nucleic acid of claim 1, wherein the nucleic acid consists of the nucleotide sequence of SEQ ID NO:

7.

5. The nucleic acid of claim 1, wherein the nucleic acid consists of a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:

8.

6. A vector comprising the nucleic acid of claim 1.

7. A vector comprising the nucleic acid of claim 2.

8. A vector comprising the nucleic acid of claim 3.

9. A vector comprising the nucleic acid of claim 4.

10. A vector comprising the nucleic acid of claim 5.

11. An isolated host cell comprising the nucleic acid of claim 1.

12. An isolated host cell comprising the nucleic acid of claim 2.

13. An isolated host cell comprising the nucleic acid of claim 3.

14. An isolated host cell comprising the nucleic acid of claim 4.

15. An isolated host cell comprising the nucleic acid of claim 5.